How weight loss pills work is a question many people ask when exploring options for managing their weight. These medicines — formally known as anti-obesity medications — do not simply 'burn fat'; instead, they target specific biological pathways involved in appetite regulation, fat absorption, or metabolic signalling. In the UK, licensed options include orlistat, liraglutide, and semaglutide, each with a distinct mechanism and eligibility criteria. Understanding how these medications function, who qualifies for them on the NHS, and what side effects to expect is essential for making an informed, safe decision alongside your GP or specialist.

How Weight Loss Pills Work in the Body

Weight loss pills, more formally known as anti-obesity medications, work through several distinct pharmacological mechanisms depending on their active ingredient. Rather than acting as a simple 'fat-burning' solution, these medicines target specific biological pathways involved in appetite regulation, fat absorption, or energy metabolism. Understanding how they function helps set realistic expectations and supports informed decision-making.

One of the most well-established mechanisms involves appetite suppression. Certain medications act on the central nervous system, influencing hormones and neurotransmitters that signal hunger and satiety. For example, glucagon-like peptide-1 (GLP-1) receptor agonists — such as semaglutide (Wegovy) — mimic a naturally occurring gut hormone that slows gastric emptying, reduces appetite, and promotes a feeling of fullness after eating. This leads to a reduced caloric intake over time. Because GLP-1 receptor agonists slow gastric emptying, they may also affect the absorption of some oral medicines taken at the same time; prescribers should review all concomitant therapy in line with the relevant Summary of Product Characteristics (SmPC) before initiating treatment.

Other medications work peripherally, in the digestive tract rather than the brain. Orlistat, for instance, inhibits pancreatic and gastric lipases — enzymes responsible for breaking down dietary fat. By blocking approximately one-third of ingested fat from being absorbed, it reduces the overall caloric contribution of fat in the diet. The unabsorbed fat is then excreted in the stool.

It is important to note that all licensed weight loss medications are indicated as adjuncts to a reduced-calorie diet, increased physical activity, and behavioural support — as specified in their UK SmPCs and reflected in NICE guidance (NG246). Clinical evidence consistently shows that these medications are most effective within this broader framework. They are not a substitute for lifestyle change but rather a tool to support it, particularly in individuals where biological factors make weight management especially challenging.

Types of Weight Loss Medication Available in the UK

In the UK, the number of licensed weight loss medications is relatively limited compared to some other countries, reflecting the stringent approval standards of the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA). Currently, the main options available include orlistat, semaglutide, and liraglutide.

Orlistat (Xenical / Alli) is the longest-established option. Xenical (120 mg) is available on prescription. Alli (60 mg) is available without a prescription but is classified as a Pharmacy (P) medicine in the UK, meaning it must be purchased under the supervision of a pharmacist rather than from a general retail shelf. Both formulations work by reducing fat absorption in the gut and do not affect appetite directly.

Liraglutide (Saxenda) is a GLP-1 receptor agonist administered as a daily subcutaneous injection. Originally developed for type 2 diabetes management, it was subsequently licensed at a higher dose for weight management. It reduces appetite and slows gastric emptying, supporting a sustained reduction in caloric intake.

Semaglutide (Wegovy) is a newer GLP-1 receptor agonist given as a once-weekly injection. Clinical trials, including the STEP programme, demonstrated significant weight loss outcomes — with participants losing an average of around 15% of body weight over 68 weeks. Wegovy has received MHRA approval and has been appraised by NICE (TA875). Importantly, NICE recommends its use only within specialist weight management services, for adults meeting defined eligibility criteria, and for a maximum treatment duration (currently up to two years under the NICE appraisal). Full details of commissioning criteria are set out in the relevant NICE Technology Appraisal.

The landscape of licensed weight management medicines in the UK is evolving. Patients and clinicians should verify the current UK licensing and availability status of any agent — including newer medicines such as tirzepatide — at the time of prescribing or dispensing, using up-to-date MHRA and NICE sources.

It is also worth noting that some medications promoted online as weight loss pills are not licensed in the UK and may carry serious health risks. Patients should always verify that any medication they are considering is MHRA-approved and obtained through a legitimate, regulated pharmacy or healthcare provider.

Who May Be Eligible for Weight Loss Medication on the NHS

Access to weight loss medication on the NHS is guided by NICE clinical guidelines and is not available to everyone who wishes to lose weight. Eligibility is based on clinical need, body mass index (BMI), and the presence of weight-related health conditions, ensuring that treatment is directed towards those most likely to benefit.

According to NICE guidance (NG246), orlistat may be considered for adults with:

• A BMI of 30 kg/m² or above, or

• A BMI of 28 kg/m² or above in the presence of weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea

This threshold of 28 kg/m² with comorbidities reflects both NICE NG246 and the UK SmPC for orlistat; earlier versions of this article incorrectly stated 27 kg/m².

For semaglutide (Wegovy), NICE (TA875) recommends its use within specialist weight management services for adults with a BMI of 35 kg/m² or above and at least one weight-related condition. A lower BMI threshold applies for certain ethnic groups at higher cardiometabolic risk at lower BMI values — NICE guidance specifies a reduction of approximately 2.5 kg/m² for these groups. Treatment is time-limited, currently to a maximum of two years under the NICE appraisal, and must be delivered as part of a specialist multidisciplinary programme.

It is also important to understand that NHS availability varies by region. Integrated Care Boards (ICBs) across England are responsible for commissioning weight management services, and access to newer injectable medications in particular may be subject to local prioritisation and phased rollout due to supply constraints and budget considerations.

Patients who do not meet NHS criteria may explore private prescription options, though costs can be significant. Regardless of the route, a thorough medical assessment is essential before starting any weight loss medication. This includes reviewing existing medical conditions, current medications, and contraindications to ensure patient safety.

Potential Side Effects and Safety Considerations

As with all medications, weight loss pills carry a risk of side effects, and understanding these is an important part of making an informed choice. The nature and severity of side effects vary considerably depending on the type of medication.

Experiencing these side effects? Our pharmacists can help you navigate them →

Orlistat most commonly causes gastrointestinal side effects, which are directly related to its mechanism of action. These include:

• Oily or fatty stools

• Frequent or urgent bowel movements

• Flatulence and oily spotting

These effects are often more pronounced when high-fat meals are consumed and can serve as a behavioural prompt to adhere to a lower-fat diet. Orlistat may also reduce the absorption of fat-soluble vitamins (A, D, E, and K), so a daily multivitamin taken at a different time to the medication (for example, at bedtime) is generally recommended.

Important interactions with orlistat include: warfarin (orlistat may alter anticoagulant effect; INR should be monitored closely); ciclosporin (separate administration by at least three hours and monitor ciclosporin levels); levothyroxine (separate by at least four hours and monitor thyroid function); and caution is also advised with antiepileptics and antiretrovirals, as absorption may be affected. Regarding oral contraceptives: orlistat does not directly reduce their efficacy, but if severe diarrhoea occurs, additional contraceptive precautions should be used.

Rare but serious risks associated with orlistat include severe liver injury and oxalate nephropathy (a form of kidney damage). Patients should stop orlistat and seek prompt medical advice if they develop symptoms of liver problems (such as jaundice, dark urine, or persistent abdominal pain) or symptoms suggestive of kidney stones (such as renal colic or blood in the urine). These risks are highlighted in MHRA Drug Safety Updates.

GLP-1 receptor agonists such as semaglutide and liraglutide are most commonly associated with nausea, vomiting, diarrhoea, and constipation, particularly during the dose escalation phase. These effects typically improve over time as the dose is increased gradually according to the structured titration schedule in the SmPC.

Not sure if this is normal? Chat with one of our pharmacists →

Additional important risks with GLP-1 receptor agonists include:

• Gallbladder disease: cholelithiasis (gallstones) and cholecystitis have been reported. Patients should seek prompt medical attention for severe or persistent upper abdominal pain, particularly if accompanied by fever or jaundice.

• Dehydration and acute kidney injury (AKI): nausea, vomiting, and diarrhoea can lead to dehydration, which may precipitate AKI. Patients should maintain adequate fluid intake and seek medical advice if they are unable to keep fluids down.

• Pancreatitis: although uncommon, acute pancreatitis has been reported. Severe, persistent abdominal pain — which may radiate to the back — should be assessed urgently.

• Diabetic retinopathy: worsening of diabetic retinopathy has been observed in people with type 2 diabetes treated with semaglutide; appropriate monitoring is advised in this group.

Regarding thyroid safety: animal studies have identified C-cell changes at supratherapeutic doses, but no causal link has been established in humans. UK SmPCs for semaglutide and liraglutide advise caution in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2); this is a precautionary warning rather than a formal contraindication under UK labelling.

Pregnancy and breastfeeding: GLP-1 receptor agonists used for weight management are contraindicated in pregnancy. Women of childbearing potential should use effective contraception during treatment. Due to the prolonged half-life of semaglutide, the SmPC advises discontinuing treatment at least two months before a planned pregnancy. These medicines are also not recommended during breastfeeding. Patients should discuss contraception and family planning with their prescriber before starting treatment.

Patient safety advice: Anyone experiencing severe abdominal pain, persistent vomiting, signs of an allergic reaction, jaundice, or significant mood changes whilst taking weight loss medication should seek prompt medical attention. It is essential to inform your GP or pharmacist of all other medications being taken, including over-the-counter products and supplements.

Patients and healthcare professionals are encouraged to report suspected side effects from any medicine to the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk). This helps the MHRA monitor the ongoing safety of medicines used in the UK.

Talking to Your GP About Weight Management Options

If you are considering weight loss medication, speaking openly with your GP is the most important first step. A GP can assess your overall health, calculate your BMI, review your medical history, and discuss whether medication is appropriate — or whether other interventions might be more suitable at this stage.

Before your appointment, it can be helpful to:

• Keep a brief food and activity diary for a few days to give your GP a clearer picture of your current lifestyle

• Note any weight-related symptoms you have experienced, such as breathlessness, joint pain, or disrupted sleep

• List all current medications and supplements, including anything purchased over the counter or online

• Be honest about previous weight loss attempts, including what worked, what did not, and for how long

Your GP may refer you to a structured weight management programme before or alongside prescribing medication. NHS Tier 2 and Tier 3 weight management services offer dietary advice, behavioural support, and physical activity guidance, which form the foundation of any effective long-term weight management plan. In line with NICE NG246, pharmacotherapy should be embedded within these tiered services rather than used in isolation.

If your GP feels that medication is appropriate, they will explain the options available, the expected benefits, the likely side effects, and how progress will be monitored. For GLP-1 receptor agonists, treatment begins at a low dose and is increased gradually over several weeks or months according to a structured escalation schedule; regular follow-up during this period is important to assess tolerability and effectiveness.

Weight loss medication is typically reviewed after 12 weeks — if a clinically meaningful response has not been achieved (generally defined as at least 5% weight loss for orlistat, and a similar threshold for GLP-1 receptor agonists), treatment is usually discontinued. For semaglutide prescribed under the NICE Technology Appraisal, treatment is also subject to a maximum duration, currently up to two years.

Finally, it is worth approaching weight management as a long-term health goal rather than a short-term fix. Medications can be a valuable and evidence-based tool, but sustainable results are most reliably achieved through a combination of medical support, lifestyle change, and ongoing follow-up with your healthcare team.

Frequently Asked Questions